As the second leading cause of years lived with disability, migraine is associated with a substantial personal burden for patients, their families, social circles, and employers. The current study aimed to evaluate patient perceptions of the impact and burden of migraine, as well as patient perception of migraine diagnosis and treatment, stigma, and migraine awareness and support [1].
A brief digital survey (~12 minutes) was completed by approximately 12,500 adult patients diagnosed with migraine who self-reported â„4 days of migraine per month. Data was collected between November and December 2019 across 16 countries in Europe, South America, Asia, and Australia. The majority of patients was 25Ââ54 years of age (74%) and female (73%).
A total of 70% of patients reported progression of migraine symptoms over time. Importantly, only 59% of patients reported to be satisfied with their prescription treatment for migraine. A comparable percentage of participants (61%) was satisfied with the physician treating their migraine.
Patients most commonly reported that migraine impacted the following areas of their lives:
- overall health and wellbeing (69%);
- social life (60%);
- work and career (56%); and
- relationship with family (39%).
Patients reported that the following people in their lives were the most impacted by their migraine:
- partner (68%);
- children (55%);
- parents (22%);
- employer (22%);
- friends (19%); and
- other family members (19%).
Almost half of the patients (46%) reported having hidden their migraine, most commonly from their employer (63%), family (49%), or friends (37%). A proportion of patients (44%) felt that the healthcare community could play the largest role in raising awareness of migraine.
These results indicate that migraine has a substantial negative impact on patientsâ lives and their familial, social, and professional environment and represents a substantial burden.
- Mitsikostas DD. Patient perceptions of the impact and burden of migraine: an international survey of 12,545 patients across 16 countries. MTIS Virtual Symposium 2020, abstract MTV20-DP-089.
Posted on
Previous Article
« Long-term efficacy and safety of fremanezumab in treatment-resistant migraine Next Article
Sustained shift in migraine status using galcanezumab »
« Long-term efficacy and safety of fremanezumab in treatment-resistant migraine Next Article
Sustained shift in migraine status using galcanezumab »
Table of Contents: MTIS 2020
Featured articles
Contents
Improvement of migraine using CGRP mAbs in a real-world setting
Similar treatment needs for high-frequency episodic and low-frequency chronic migraine
Nitroglycerin-induced cluster headache attacks characterised comprehensively
Remote electrical neuromodulation useful for adolescents with migraine
Concomitant preventive medication has no impact on efficacy of ubrogepant
No new cardiovascular safety concerns with long-term use of lasmiditan
Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine
Real-world evidence reveals physiciansâ perception of erenumab
Early initiation of lasmiditan improves migraine outcomes
Fremanezumab effective in patients with migraine and comorbid depression
Long-term onabotulinumtoxinA improves quality of life in migraine
Sustained shift in migraine status using galcanezumab
Long-term efficacy and safety of fremanezumab in treatment-resistant migraine
Related Articles
July 30, 2019
Fremanezumab efficacy and safety maintained over 1 year
September 9, 2020
Eptinezumab in chronic migraine and medication-overuse headache
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com